MedDataX Logo

Cetirizine Chewable Bioequivalence and Food Effect Study

NCT ID: NCT03772158

Last Updated: 2021-12-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-11

Study Completion Date

2019-02-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine and compare the amount of study drug that gets into your blood after the administration of each of the three formulations of cetirizine under different conditions. Another objective of this study is to evaluate the effect of food on the amount of study drug that gets into your blood after the administration of the investigational formulation. Other objectives of this study are to determine the sensory experience and ease of swallowing the investigational formulation, as well as to determine the safety of test and reference formulations of cetirizine.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to establish bioequivalence of a cetirizine 10 mg chewable tablet manufactured at Johnson \& Johnson Consumer Inc. (McNeil LLC) with two commercially marketed cetirizine 10 mg immediate release (IR) tablets (ZYRTEC®, US reference) and (Australian/EU reference), establish bioequivalence between the two commercial products (ZYRTEC®, US reference and REACTINE®, Australian/EU reference), and to evaluate the effect of food on bioavailability of the cetirizine 10 mg chewable tablet compared to the bioavailability of cetirizine 10 mg chewable tablet administrated with water only. In addition, subject's sensory experience and ease of swallowing of the test product will be assessed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Allergy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bioequivalence study Healthy volunteers Cetirizine Tablet

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

This is a randomized, single-dose, four-treatment crossover bioequivalence and food effect study of Cetirizine Chewable Tablets versus ZYRTEC® Immediate Release (IR) Tablets (US reference) and REACTINE® IR Tablets (EU and Australian marketed reference product).

The study will be conducted in two parts. Part 1 of the study will have a randomized, four way crossover study design in which 40 healthy subjects, ages 18 to 55 years, will be randomized to four sequences of Treatments A, B, D and E over consecutive periods. No less than approximately 40% of either gender will be represented in the study population. Part 2 of the study will assess a potential food effect in which all subjects will be administered Treatment C in the fifth period.
Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Outcome Assessors
Blinding of the test and reference products to study subjects is not feasible, because the products are different dosage forms (chewable tablets and IR tablets) and administered in different ways (with or without water and fasted or fed). Personnel conducting the bioanalyses of samples will not know the treatment sequence. The randomization code will not be available to them until the analytical tables have been finalized and audited by the Algorithme Pharma (An Altasciences Company) Quality Assurance (QA) department.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.

Group Type EXPERIMENTAL

Cetirizine 10mg

Intervention Type DRUG

Chewable tablet

Treatment B

Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.

Group Type EXPERIMENTAL

Cetirizine 10mg

Intervention Type DRUG

Chewable tablet

Treatment C

Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.

Group Type EXPERIMENTAL

Cetirizine 10mg

Intervention Type DRUG

Chewable tablet

Treatment D

Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.

Group Type ACTIVE_COMPARATOR

Cetirizine 10 mg

Intervention Type DRUG

Immediate Release Tablet

Treatment E

Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.

Group Type ACTIVE_COMPARATOR

Cetirizine 10 mg

Intervention Type DRUG

Immediate Release Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetirizine 10mg

Chewable tablet

Intervention Type DRUG

Cetirizine 10 mg

Immediate Release Tablet

Intervention Type DRUG

Cetirizine 10 mg

Immediate Release Tablet

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test product ZYRTEC 10 mg REACTINE 10 mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy male or female subject between the ages of 18 and 55 years, inclusive. Health is defined as the absence of clinically relevant abnormalities as judged by the Investigator on the basis of a detailed medical history, physical examination, blood pressure, pulse rate measurements, 12-lead electrocardiogram (ECG), as well as clinical laboratory tests. The responsible Investigator may request additional investigations or analyses if necessary.
2. Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco or nicotine-containing product for at least 6 months before screening visit of this study.
3. For females: Postmenopausal state (i.e. at least 1 year without menses without an alternative medical condition prior to the first study drug administration) or premenopausal /perimenopausal state with an effective means of contraception (as defined in Section 10.5.5).
4. For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study.
5. Body Mass Index (BMI) ≥ 18.5 and ≤ 30 kg/m2 with a total body weight \>50 kg.
6. A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified within the protocol.

20. Has a positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (anti-HCV).
21. Has a positive test for alcohol or drugs of abuse at screening or prior to the first study drug administration.

Exclusion Criteria

1. Use of prescription or non-prescription medications within 5 half-lives before the first IP administration unless these are contraceptives or occasional use of other medications approved by the Investigator.
2. Use of any vitamins, dietary and herbal supplements within seven days before first dose of study drug.
3. History of any allergy or hypersensitivity (e.g. skin reaction, asthma, angioedema) to cetirizine or any excipients of the formulations.
4. If female: is pregnant, has a positive pregnancy test at screening or prior to the first study drug administration, or is planning to become pregnant during the duration of the study, and/or is breast-feeding.
5. Has a history of gastrointestinal surgery other than appendectomy.
6. Has hypertension, fluid retention, or heart disease either by history or by the medically qualified Investigator's medical judgment.
7. Currently suffering from asthma or has a medically significant history of asthma in the opinion of the investigator.
8. Has clinically significant renal or hepatic impairment; according to the medically qualified Investigator discretion.
9. Was treated with an investigational product within 28 days or within a period less than 5 times the drug's half-life, whichever is longer, preceding the first dose of study drug.
10. Preplanned surgical procedures during the study period as this may interfere with the conduct of the study.
11. History of alcoholism or substance abuse, as judged by the Investigator, within the past 6 months preceding this study.
12. Consumed alcohol beverage(s) within 48 hours preceding the first dose of study drug.
13. History of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
14. Any history of tuberculosis.
15. Donation or loss of blood within 28 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 50 mL.
16. Donation or loss of blood within 56 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 500 mL.
17. Has any acute or chronic medical or psychiatric condition(s) that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the medically qualified Investigator, would make the subject inappropriate for entry into this study.
18. Relationship to persons involved directly in the conduct of the study (i.e., principal Investigator, sub-Investigators, study coordinators, other study personnel, employees or contractors of the sponsor or Johnson \& Johnson subsidiaries, and the family of each).
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Sicard, MD

Role: PRINCIPAL_INVESTIGATOR

Algorithme Pharma Inc

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Algorithme (An altascience Company)

Mount Royal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Related Links

Access external resources that provide additional context or updates about the study.

https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217051&parentIdentifier=CCSURA000499&attachmentIdentifier=b1bd7d49-7220-4c5f-8c78-555f34b49b1d&fileName=CSR_CCSURA000499_Section_2_Synopsis_Redacted.pdf&versionIdentifier=

CSR synopsis for Bioequivalence Study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCSURA000499

Identifier Type: -

Identifier Source: org_study_id